Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Accumulated Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Accumulated Expenses for 13 consecutive years, with $10.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 31.73% to $10.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.3 million, a 31.73% increase, with the full-year FY2024 number at $7.0 million, changed N/A from a year prior.
  • Accumulated Expenses was $10.3 million for Q3 2025 at Theravance Biopharma, up from $7.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $15.6 million in Q1 2021 to a low of $3.9 million in Q2 2021.
  • A 5-year average of $7.3 million and a median of $7.0 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 85.42% in 2021, then soared 78.41% in 2022.
  • Theravance Biopharma's Accumulated Expenses stood at $8.6 million in 2021, then increased by 19.44% to $10.3 million in 2022, then tumbled by 36.22% to $6.6 million in 2023, then rose by 6.7% to $7.0 million in 2024, then soared by 47.17% to $10.3 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Accumulated Expenses are $10.3 million (Q3 2025), $7.3 million (Q2 2025), and $5.4 million (Q1 2025).